Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Can Circulating Tumor DNA Improve the Predictive Value of Interim Response in Patients with Advanced Hodgkin Lymphoma and PET-2 DS3?

Heidi Mocikova, Kristyna Kupcova, Jana Markova, Lubica Gaherova, Maria Maco, Iva Hamova, Adriana Velasova, Alice Sykorova, Pavla Stepankova, Alexandra Kredatusova, Vit Prochazka, Jan Koren, Petr Nehasil, Petra Zemankova, Tomas Kozak, Ondrej Havranek

Blood (2024) 144 (Supplement 1): 6193.

https://doi.org/10.1182/blood-2024-210890

Published: 2024

Journal Articles

The Outcome of Diffuse Large B-Cell Lymphoma Patients with Testicular Involvement - Real World Data

Heidi Mocikova, Andrea Janikova, Alice Sykorova, Vit Prochazka, Jan Pirnos, Juraj Duras, Katerina Kopeckova, Katerina Steinerova, Robert Pytlik, Petra Blahovcova, David Salek, Tomas Kozak, Veronika Bachanova, David Belada

Blood (2023) 142 (Supplement 1): 4482.

https://doi.org/10.1182/blood-2023-180155

Published: 2023

Journal Articles

Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia

Wojciech Jurczak, Andrzej Pluta, Malgorzata Wach, Daniel Lysak, Tomas Kozak, Martin Šimkovič, Iryna Kriachok, Arpad Illes, Javier de la Serna, Sean Dolan, Philip Campbell, Gerardo Musuraca, Abraham Jacob, Eric J. Avery, Jae Hoon Lee, Min Hui Wang, Ting Yu, Paolo Ghia

Blood (2021) 138 (Supplement 1): 393.

https://doi.org/10.1182/blood-2021-146570

Published: 2021

Journal Articles

Is It Better to Start Treatment with ABVD and Continue with PET2-Adapted Approach or Should We Use 2 Cycles of Beacopp Escalated and 2 Cycles of ABVD and Irradiation in Early Unfavorable Hodgkin Lymphoma?

Heidi Mocikova, Jana Markova, Lubica Gaherova, Maria Maco, Alice Sykorova, David Belada, Marie Lukasova, Vit K Prochazka, Katarina Hradska, Juraj Ďuraš, Ondrej Havranek, Tomas Kozak

Blood (2021) 138 (Supplement 1): 4539.

https://doi.org/10.1182/blood-2021-148363

Published: 2021

Journal Articles

Early Progression after R-CHOP in Follicular Lymphoma: Key Role for the Maintenance Therapy

Vit K Prochazka, MD PhD Assoc Prof, Tomas Papajik, MD prof., Andrea Janikova, MD PhD, Assoc Prof, David Belada, Tomas Kozak, MD, PhD, Prof., David Salek, MD PhD, Alice Sykorova, MD PhD, Heidi Mocikova, MD, PhD, Vit Campr, MD PhD, Jitka Dlouha, Tomas Fuerst, MSc, PhD, Marek Trneny

Blood (2016) 128 (22): 1779.

https://doi.org/10.1182/blood.V128.22.1779.1779

Published: 2016

Journal Articles

Outcome of Patients with Hodgkin Lymphoma transformed from Chronic Lymphocytic Leukemia

Heidi Mocikova, MD, PhD, Jana Markova, MD, Lubica Gaherova, MD, Lukas Smolej, MD, PhD, Assoc.Prof., Martin Simkovic, MD, Tomas Kozak, MD, PhD, Prof.

Blood (2015) 126 (23): 5298.

https://doi.org/10.1182/blood.V126.23.5298.5298

Published: 2015

Journal Articles

Low-Dose FCR Is a Safe and Effective Treatment Option for Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Updated Results of Project Q-Lite By Czech CLL Study Group

Lukas Smolej, MDPhD, Yvona Brychtova, MD PhD, Michael Doubek, Prof., MD PhD, Eduard Cmunt, MDPhD, Martin Spacek, MD, PhD, David Belada, MD, Monika Motyckova, MDPhD, Irena Zygulova, MD, Dagmar Adamova, MD, Vit Prochazka, MDPhD, Martin Simkovic, MD, Katerina Klaskova, MS, Tomas Kozak, MDPhD

Blood (2014) 124 (21): 4670.

https://doi.org/10.1182/blood.V124.21.4670.4670

Published: 2014

Journal Articles

Defining Criteria for Diagnosis of Occult Lymphomatous Involvement in Cerebrospinal Fluid

Heidi Mocikova, MD, PhD, Magdalena Klanova, MD, Martin Spacek, MD, PhD, Robert Pytlik, MD, PhD, Tomas Kozak, MD, PhD, Prof., Marek Trneny, MD, PhD, Prof., Vit Pospisil, PhD

Blood (2014) 124 (21): 5412.

https://doi.org/10.1182/blood.V124.21.5412.5412

Published: 2014

Journal Articles

Rituximab Maintenance after Chemoimmunotherapy Induction in 1 st and 2 nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial

Blood (2014) 124 (21): 20.

https://doi.org/10.1182/blood.V124.21.20.20

Published: 2014

Journal Articles

Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL

Christian H. Geisler, Mars B. van t’ Veer, Jesper Jurlander, Jan Walewski, Geir Tjønnfjord, Maija Itälä Remes, Eva Kimby, Tomas Kozak, Aaron Polliack, Ka Lung Wu, Shulamiet Wittebol, Martine C. J. Abrahamse-Testroote, Jeanette Doorduijn, Wendimagegn Ghidey Alemayehu, Marinus H. J. van Oers

Blood (2014) 123 (21): 3255–3262.

https://doi.org/10.1182/blood-2014-01-547737

Published: 2014

Includes: Supplemental data

Journal Articles

Frontline Intensive Chemotherapy Brings Survival Benefit In Young, Risky Patients With Follicular Lymphoma: Pair-Matched Analysis From The Czech Lymphoma Study Group (CLSG) Database

Vit Prochazka, M.D., Ph.D., Marek Trneny, MD, Ph.D., Prof., Andrea Janikova, MD, PhD, David Belada, M.D., Ph.D., Tomas Kozak, M.D., Ph.D., ass. prof., Tomas Papajik, MD, PhD, ass. prof., Vit Campr, MD, Ph.D., David Salek, MD, Ph.D., Robert Pytlik, MD, Ph.D., Alice Sykorova, MD, PhD, Milada Jankovska, MD, Jitka Dlouha

Blood (2013) 122 (21): 4354.

https://doi.org/10.1182/blood.V122.21.4354.4354

Published: 2013

Journal Articles

Oncogenic Micrornas In Cerebrospinal Fluid and Sera Reflect Therapy Efficacy and Their Reappearance Precedes Clinical Relapse In Primary and Secondary CNS Lymphoma

Vit Pospisil, MSc., PhD, Heidi Mocikova, MD, PhD, Magdalena Klanova, MD, Monika Palickova, MD, Tomas Kozak, M.D., Ph.D., ass. prof., Marek Trneny, MD, Ph.D., Prof., Tomas Stopka, MD, PhD

Blood (2013) 122 (21): 1777.

https://doi.org/10.1182/blood.V122.21.1777.1777

Published: 2013

Journal Articles

Romiplostim for the Treatment of Adults with Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice – Interim Results From a Large, European, Observational Study

Dominik Selleslag, Ann Janssens, Hans Wadenvik, Michael Steurer, MD, Philippe Quittet, MD, Georgia Kaiafa, Tomas Kozak, MD, Helen Papadaki, Jean-François Viallard, MD, PhD, Kerry Dillingham, Georg Kreuzbauer, MD

Blood (2012) 120 (21): 3316.

https://doi.org/10.1182/blood.V120.21.3316.3316

Published: 2012

Journal Articles

Outcome of Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated with or without Rituximab

Heidi Mocikova, MD, PhD, Jozef Michalka, MD, Jan Koren, Pavla Stepankova, Alexander Wild, Ludek Raida, MD, Jana Markova, MD, Zdenek Kral, Marek Trneny, MD, Karel Indrak, MD, Prof., Jiri Mayer, M.D., PhD., Prof., Tomas Kozak, M.D., Ph.D.

Blood (2012) 120 (21): 4878.

https://doi.org/10.1182/blood.V120.21.4878.4878

Published: 2012

Journal Articles

MicroRNA Analysis in the Cerebrospinal Fluid and Blood Serum of Lymphoma Patients At Diagnosis and in Response to Therapy,

Vit Pospisil, Heidi Mocikova, MD, PhD, Milada Jankovska, MD, Jana Markova, MD, Lubica Gaherova, MD, Tomas Kozak, MD, PhD, Tomas Stopka, MD, PhD

Blood (2011) 118 (21): 3663.

https://doi.org/10.1182/blood.V118.21.3663.3663

Published: 2011

Journal Articles

Final Results from an International, Multi-Center, Single-Arm Study Evaluating the Safety and Efficacy of Romiplostim in Adults with Primary Immune Thrombocytopenia (ITP),

Ann Janssens, MD, Michael D. Tarantino, MD, Robert Bird, MD, Maria Gabriella Mazzucconi, MD, Ralph Vincent V. Boccia, MD, Maria Fernanda Lopez-Fernandez, MD, Tomas Kozak, MD, Michael Steurer, MD, Peter A.W. Te Boekhorst, MD, PhD, Kerry Dillingham, MSc, Richard Lizambri, MD

Blood (2011) 118 (21): 3279.

https://doi.org/10.1182/blood.V118.21.3279.3279

Published: 2011

Journal Articles

Immunochemotherapy with Low-Dose Subcutaneous Alemtuzumab (A) Plus Oral Fludarabine and Cyclophosphamide (FC) Is Safe and Induces More and Deeper Complete Remissions in Untreated Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Than Chemotherapy with FC Alone. An Early Analysis of the Randomized Phase-III HOVON68 CLL Trial

Christian H Geisler, MD, PhD, Mars MB van 't Veer, MD, PhD, Wim van Putten, MSc, Jesper Jurlander, MD.PHD, Jan Walewski, MD, PhD, Geir Tjonnfjord, MD, PHD, Maija Itälä-Remes, MD, PHD, Eva Kimby, M.D., Ph.D., Tomas Kozak, MD, PhD, Aaron Polliack, MD, Shulamiet Wittebol, MD, Fokje Spoelstra, PhD, Marinus H.J. Van Oers, MD, PhD

Blood (2011) 118 (21): 290.

https://doi.org/10.1182/blood.V118.21.290.290

Published: 2011

Journal Articles

Identification of Novel Molecular Markers for the Follow-up of Minimal Residual Disease in Hematooncological Disorders

David Warren Hardekopf, Tereza Jancuskova, Marie Jarosova, Lucie Krutilkova, Radek Plachy, Lenka Zejskova, Radek Cmejla, PhD, Jan Vydra, Tomas Kozak, MD, PhD, Michal Karas, Vladimir Koza, MD, Alzbeta Zavrelova, MD, Pavel Zak, MD, PhD, Lukas Smolej, M.D., Ph.D., Sona Pekova

Blood (2011) 118 (21): 4905.

https://doi.org/10.1182/blood.V118.21.4905.4905

Published: 2011

Journal Articles

Median Absolute Lymphocyte Count Independently Predicts Survival of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-Chemotherapy: Analysis of 651 Patients Included In the Czech Lymphoma Project

Blood (2010) 116 (21): 2882.

https://doi.org/10.1182/blood.V116.21.2882.2882

Published: 2010

Journal Articles

The Outcome of Unselected Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib In the First Line and the Prognostic Value of ELN Defined Responses – Population Based Analysis of 458 Patients Treated Between 2003–2009.

Blood (2010) 116 (21): 1239.

https://doi.org/10.1182/blood.V116.21.1239.1239

Published: 2010

NARROW

Can Circulating Tumor DNA Improve the Predictive Value of Interim Response in Patients with Advanced Hodgkin Lymphoma and PET-2 DS3?

The Outcome of Diffuse Large B-Cell Lymphoma Patients with Testicular Involvement - Real World Data

Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia

Is It Better to Start Treatment with ABVD and Continue with PET2-Adapted Approach or Should We Use 2 Cycles of Beacopp Escalated and 2 Cycles of ABVD and Irradiation in Early Unfavorable Hodgkin Lymphoma?

Early Progression after R-CHOP in Follicular Lymphoma: Key Role for the Maintenance Therapy

Outcome of Patients with Hodgkin Lymphoma transformed from Chronic Lymphocytic Leukemia

Low-Dose FCR Is a Safe and Effective Treatment Option for Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Updated Results of Project Q-Lite By Czech CLL Study Group

Defining Criteria for Diagnosis of Occult Lymphomatous Involvement in Cerebrospinal Fluid

Rituximab Maintenance after Chemoimmunotherapy Induction in 1 st and 2 nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial

Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL

Frontline Intensive Chemotherapy Brings Survival Benefit In Young, Risky Patients With Follicular Lymphoma: Pair-Matched Analysis From The Czech Lymphoma Study Group (CLSG) Database

Oncogenic Micrornas In Cerebrospinal Fluid and Sera Reflect Therapy Efficacy and Their Reappearance Precedes Clinical Relapse In Primary and Secondary CNS Lymphoma

Romiplostim for the Treatment of Adults with Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice – Interim Results From a Large, European, Observational Study

Outcome of Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated with or without Rituximab

MicroRNA Analysis in the Cerebrospinal Fluid and Blood Serum of Lymphoma Patients At Diagnosis and in Response to Therapy,

Final Results from an International, Multi-Center, Single-Arm Study Evaluating the Safety and Efficacy of Romiplostim in Adults with Primary Immune Thrombocytopenia (ITP),

Identification of Novel Molecular Markers for the Follow-up of Minimal Residual Disease in Hematooncological Disorders

Median Absolute Lymphocyte Count Independently Predicts Survival of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-Chemotherapy: Analysis of 651 Patients Included In the Czech Lymphoma Project

The Outcome of Unselected Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib In the First Line and the Prognostic Value of ELN Defined Responses – Population Based Analysis of 458 Patients Treated Between 2003–2009.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only